Published in Cancer Weekly, December 28th, 1998
The FDA is working to develop a regulatory framework that ensures the safety and efficacy of these vaccines, and has turned to members of academia and industry for advice. AVAX presented data obtained in its development program pertaining to the manufacture and characterization of its vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.